Ikaros deficiency is associated with aggressive BCR-ABL1 B-cell precursor acute lymphoblastic leukemia independent of the lineage and developmental origin

The B-cell lineage is established from waves of differentiation that begin in the fetal liver (FL) and continue in the postnatal bone marrow (BM). In mice, FL lymphopoiesis gives rise to B1 cells, which produce natural polyreactive immunoglobulin M (IgM) antibodies and are implicated in innate immunity. Conversely, BM lymphopoiesis favors conventional B2-cell development over B1, and is essential for adaptive immunity.1,2 The features that distinguish B1- and B2-cell differentiation remain partially understood. Ikaros, encoded by IKZF1, is a key transcriptional regulator of B lymphopoiesis in mice and humans.3 It promotes B2-cell development at multiple stages, including large pre-B-cell (Hardy fraction C’) differentiation where it antagonizes IL-7/STAT5 signaling.4 Ikaros is also a tumor suppressor in B2 progenitors, and deleterious IKZF1 alterations are prominent in BCR-ABL1+ B-cell precursor acute lymphoblastic leukemias (BCP-ALL) with constitutively active STAT5.5 While Ikaros is likewise important for fetal and adult B1-cell development, the exact stage where it is required has remained unclear, due to a dearth of in-depth knowledge about B1-cell differentiation. Whether Ikaros acts as a tumor suppressor in B1 cells, or in fetal B cells in general, is currently unknown. Here we show that B1-cell differentiation parallels that of B2 cells in terms of phenotype and cell cycle status. We show that Ikaros promotes B1-cell differentiation at a stage equivalent to fraction C’ of B2 cells, by modulating the expression of genes involved in cell proliferation and migration, pre-B-cell receptor (BCR) signaling, Ig-HC rearrangement and IL-7/STAT5 signaling. We also show that Ikaros inhibits the expansion of murine BCR-ABL1+ B1 progenitors from the FL and BM, and suggest that this function might be conserved in human FL-derived B cells.

In order to determine the role of Ikaros in adult B1-cell differentiation, we analyzed the BM of Ikf/fMb-1-Cre+ conditional knockout (cKO) and Ikf/fMb-1-Cre wild-type (WT) mice (Figure 1A), where the Cre recombinase is controlled by the endogenous Cd79a promoter.4 While the percentage of WT B1 progenitors (LinIgM-CD93-CD19+B220-) remained low with age, the same population in the cKO mice was ~20x higher until 4 weeks of age, before decreasing to WT levels by week 16 (Figure 1B). This increase was not due to a compensatory decrease in B2 progenitors, as the percentage of BM B2 progenitors (B220+CD19+CD43+) was stable over time (Online Supplementary Figure S1A). Ikaros loss in B1 progenitors was confirmed by intracellular staining (Online Supplementary Figure S1B). These results showed that Ikaros is required for differentiation in B1 progenitors from an early pro-B1 cell stage.

In order to pinpoint the stage where Ikaros promotes B1-cell differentiation, we dissected the above B1 progenitor cell population, by analyzing Ig-HC rearrangement, and evaluating CD24 and BP-1 expression, typically used to define B2-cell development.6 WT or cKO B1 progenitors were heterogeneous with unrearranged, germline HC genes, and rearranged DJ as well as proximal and distal VDJ genes (Figure 2A). WT B1 progenitors were mostly CD24−BP-1− and CD24+BP-1+, resembling Hardy fractions A and B among B2 progenitors (Figure 2B). Interestingly, cKO cells were mainly CD24+BP-1+ and CD24+BP-1+, and resembled B2 fractions C and C’. Hence, B1 progenitors are more heterogeneous than pre-

---

Figure 1. B1 progenitors accumulate in Ikaros conditional knockout bone marrow. (A) Representative flow cytometry analysis of bone marrow (BM) B1 progenitors (LinIgM-CD93-CD19+B220-) from 4-week-old mice. Numbers correspond to % of parental population. (B) % BM B1 progenitors in wild-type (WT) or conditional knockout (cKO) mice with age (D: days; W: weeks after birth). Significance was calculated using unpaired Student’s t-test. ns: not significant; *P<0.05; ***P<0.001; ****P<0.0001. Ikf/fMb-1-Cre mice4 were housed in specific pathogen-free (SPF) conditions or kept in single-ventilated cages. IgM: immunoglobulin M.
viously described, and correspond to phenotypic stages like those of B2 fractions. These results suggested that Ikaros deficiency blocks B1-cell differentiation at the fraction C’ stage, similar to its effect on B2-cell development, using the same Cre transgene.

In order to evaluate the molecular pathways regulated by Ikaros, we analyzed the gene expression changes between WT and cKO BM B1 progenitors by RNA sequencing (RNA-seq) (Online Supplementary Figure S2). Pathway enrichment and gene set enrichment analyses (GSEA) associated Ikaros with cell migration, adhesion, proliferation, and B-cell differentiation and maturation (Figure 2C and D). As Ikaros antagonizes STAT5 binding to DNA in pre-B2 cells, we asked if Ikaros has a similar
function in B1 progenitors. GSEA of STAT5-induced genes antagonized by Ikaros in pre-B2 cells revealed their enrichment among the upregulated genes in Ikaros deficient B1 cells, suggesting that Ikaros also antagonizes STAT5 gene activation in B1 progenitors. Thus, Ikaros appears to affect similar biological pathways in B1 and B2 progenitors.

That Ikaros deficiency correlates with increased STAT5-activated gene expression suggests that Ikaros may act as a tumor suppressor in B1 cells. We transduced BM WT and cKO B1 progenitors to express the BCR-ABL1 oncoprotein, or an empty vector (pMITo), carrying a TdTomato (TdTo) reporter. Transduction efficiency was assessed and BCR-ABL1 expression was confirmed by western blot (Online Supplementary Figure S3A and B). TdTo⁺ cells were injected into NSG mice and the health status was monitored over time. All mice that received cKO B1 BCR-ABL1⁺ cells developed BCP-ALL, as characterized by BM failure (anemia, thrombocytopenia, splenomegaly) (Online Supplementary Figure S3C), which was sometimes associated with hepatomegaly and neurological impairment. Blast cell (CD19⁺TdTo⁺) infiltration was observed in the BM and spleen (Figure 3A). In contrast, only 25% of mice transplanted with WT B1 BCR-ABL1⁺ cells developed BCP-ALL, with slower kinetics and fewer symptoms (Figure 3B). We also analyzed symptom-free mice that received WT B1 BCR-ABL1⁺ or cKO B1 pMITo⁺ cells, but did not detect CD19⁺TdTo⁺ cells in the BM or spleen (Figure 3A). The fact that not all mice that received WT B1 BCR-ABL1⁺ cells developed leukemia, as previously described, may be due to the limiting numbers of cells injected here. Our results therefore indicated that Ikaros limits the ability of BM B1 progenitors to develop BCR-ABL1-induced BCP-ALL.

In order to determine if Ikaros also functions as a tumor suppressor in fetal-derived B1 cells, we transduced WT and cKO FL B1 progenitors (from E17-E18 organs) to express BCR-ABL1 and injected them into NSG mice. Fetal B1 progenitors gave rise to BCP-ALL similar to BM B1 cells. Ikaros deficiency was associated with a higher tumor burden and decreased survival (Figure 3B). These results demonstrated that Ikaros reduces BCP-ALL development in B1 progenitors.

Lastly, we asked if Ikaros loss is implicated in human B1-like BCP-ALL. Because human B1 cells are ill-defined, we first compared a published set of genes, differentially expressed between human B1- and non-B1-like BCP-ALL, with our available human BCP-ALL RNA-seq dataset, but this did not identify clear subgroups among samples. We then separated a collection of 370 pediatric and 102 adult BCP-ALL samples into B1-like and non-B1-like groups according to Vh usage, and further

Figure 3. Continued on following page.
analyzed them for \( \text{IKZF1} \) deletions (gross chromosomal deletions of chromosome 7, -7p, intragenic deletions) (Figure 3C). In both children and adult samples, the ratio of mutant to functional \( \text{IKZF1} \) samples was similar between B1- and non-B1-like BCP-ALL. \(^{11}\) Since \( \text{IKZF1} \) alterations are frequent in BCR-ABL1+ BCP-ALL, we checked if BCR-ABL1+ leukemias were enriched in B1-like cases. Interestingly, there was a significant enrichment of BCR-ABL1+ cases within the B1-like group when compared with the non-B1 group in both pediatric (21% vs. 13.4%) and adult (67% vs. 45%) patients (\( P<0.05 \) in both cases; hypergeometric test). Among the pediatric samples, 35 came from infants <1 year of age, and most (34/35) contained KMT2A rearrangements, considered to occur in utero. \(^{12}\) Four of these samples exhibited an \( \text{IKZF1} \) deletion (Figure 3D). Thus, our results in mice and humans showed that Ikaros loss is associated with BCP-ALL development in both fetal and adult origin.

In conclusion, our study indicates that murine B1-cell development can be divided into phenotypically discrete stages that resemble the Hardy fractions A-C currently used to evaluate B2-cell differentiation. \(^{6}\) These newly identified populations will allow further investigation into the requirements of B1-cell development and the factors involved. We show that Ikaros is required at the fraction C’ stage of B1-cell differentiation as observed for B2 progenitors, suggesting similar regulation of gene expression, particularly in antagonizing genes regulated by IL-7/STAT5. \(^{8}\) Our results also suggest that Ikaros functions as a tumor suppressor by repressing STAT5 activity in B-cell progenitors of fetal and adult origin. Whether the B1-cell equivalent exists in humans is still unclear. However, human fetal B cells and murine B1 progenitors are alike in some ways. Infant and pediatric BCP-ALL cells often co-express lymphoid and myeloid markers; \(^{13}\) similarly, murine B1 cells have been reported to be bipotent and can develop into both B cells and macrophages. \(^{14}\) While our results do not address the validity of human B1 cells, we found \( \text{IKZF1} \) alterations in both B1- and non-B1-like leukemias of children and adults, including those with fetus-associated ETV6-RUNX1 translocations and KMT2A rearrangements. Thus, Ikaros loss-of-function is associated with BCP-ALL development in patients of all ages. It will be interesting in future studies to determine if B1- and non-B1-like cases are associated with different outcomes, and if this parameter could improve the risk classification of BCP-ALL patients.

**Célestin Simand,1,2,3,4,5 Céline Keime,1,2,3,4 Aurélie Caye,6,7 Chloé Arfeuille,6,7 Marie Passet,3 Rathana Kim,5 Hélène Cavé,6,7 Emmanuelle Clappier,8 Philippe Kastner,1,2,9,10 Susanne Chat,1,3,10 and Beate Heizmann1,2,4,9**

1Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch; 2Institut National de la Santé et de la Recherche Médicale, INSERM U1258, Illkirch; 3Centre National de la Recherche Scientifique, CNRS UMR7104, Illkirch; 4Université de Strasbourg, Illkirch; 5Service d’Hématologie, Institut de Cancérologie Strasbourg Europe, IGANS, Strasbourg; 6Département de Génétiqne, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Robert Debré, Paris; 7Institut de Recherche Saint-Louis, INSERM UMR_S1134, Université de Paris, Paris; 8Université de Paris, Laboratory of Hematology, AP-HP Hôpital Saint-Louis, Paris and 9Faculté de Médecine, Université de Strasbourg, Strasbourg, France.

*SC and BH contributed equally as co-senior authors*
Corresponding author:
PHILIPPE KASTNER - scpk@igbmc.fr
doi:10.3324/haematol.2021.279125
Received: June 10, 2021.
Accepted: September 17, 2021.
Pre-published: September 30, 2021.
Disclosures: no conflicts of interest to disclose.
Contributions: CS performed experiments, interpreted the data and wrote the manuscript; CK analyzed data; AC, CA, RK and MP prepared and analyzed patients’ samples; HC and EC provided clinical data; SC and PK designed the research, interpreted the data and wrote the manuscript.

Acknowledgments: we thank members of the Chan-Kastner lab for scientific discussion and help, P. Marchal for technical support, the Group for Research in Adult ALL (GRAALL) for providing data of patients’ analysis, the IGBMC GenomEast sequencing platform, the IGBMC flow cytometry facility (C. Ebel, M. Philipps), the IGBMC animal facility (M. Gendron, S. Falcone, W. Magnant, A. Vincent), and the IGBMC cell culture facility.

Funding: CS received a predoctoral fellowship from la Ligue Nationale Contre le Cancer (LNCC). This study was supported by grants from Fondation ARC (PJA20171206572 to BH), Agence Nationale de la Recherche (ANR-20-CE15-0011 to BH), LNCC (Equipe Labelisée 2014-2017 to SC), Institut National du Cancer (PILBIO-2015-514 to PK and HC), Agence Nationale de la Recherche (ANR-17-CE15-0023-04 to SC), Fondation pour la Recherche Médicale (Equipe FRM 2019; EQU201905007812), an equipment grant from LNCC Group East/Bourgogne Franche Comté (2019-2022 to SC), institute funds from INSERM, CNRS, Université de Strasbourg, and the institute grant ANR-10-LABX-0030-INRT, a French State fund managed by the Agence Nationale de la Recherche under the frame program Investissements d’Avenir ANR-10-IDEX-2002-02. The GenomEast platform is a member of the France Génomique consortium (ANR-10-INBS-0009).

References

1. Montecino-Rodriguez E, Dorshkind K. B-1 B cell development in the fetus and adult. Immunity. 2012;36(1):15-21.
2. Baumgarth N. A Hard(y) Look at B-1 cell development and function. J Immunol. 2017;199(10):3387-3394.
3. Heizmann B, Kastner P, Chan S. The Ikaros family in lymphocyte development. Curr Opin Immunol. 2018;51:14-23.
4. Heizmann B, Kastner P, Chan S. Ikaros is absolutely required for pre-B cell differentiation by attenuating IL-7 signals. J Exp Med. 2013;210(15):2823-2832.
5. Marke R, Van Leeuwen FN, Scheijen B. The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2018;103(4):565-574.
6. Hardy RR. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med. 1991;173(5):1213-1225.
7. Montecino-Rodriguez E, Leathers H, Dorshkind K. Identification of a B-1 B cell-specified progenitor. Nat Immunol. 2007;8(3):293-301.
8. Heizmann B, Le Gras S, Simand C, Marchal P, Chan S, Kastner P. Ikaros antagonizes DNA binding by STATS in pre-B cells. PLoS One. 2020;15(11):1-15.
9. Montecino-Rodriguez E, Li K, Fice M, Dorshkind K. Murine B-1 B cell progenitors initiate B-acute lymphoblastic leukemia with features of high-risk disease. J Immunol. 2014;192(1):5171-5178.
10. Fitch B, Roy R, Geng H, et al. Human pediatric B-cell acute lymphoblastic leukemias can be classified as B-1 or B-2-like based on a minimal transcriptional signature. Exp Hematol. 2020;90:65-71.
11. Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20 + CD27 + CD43 + CD70 -. J Exp Med. 2011;208(1):67-80.
12. Gale KB, Ford AM, Repp R, et al. Backtracking leukemia to birth: Identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci U S A. 1997;94(25):13950-13954.
13. Abdellakeem M. Frequent but nonrandom expression of myeloid markers on de novo childhood acute lymphoblastic leukemia. Exp Mol Pathol. 2007;83(1):138-141.
14. Montecino-Rodriguez E. Identification of B/macrophage progenitors in adult bone marrow. Semin Immunol. 2002;14(6):571-576.
15. Zhou Y, Zhou B, Pachle L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.